Roctavian’s Durability: For The Price, Payers Wanted Longer-Term Proof Anyway

FDA’s decision to seek two more years of data for BioMarin’s gene therapy for hemophilia A ‘makes perfect sense,’ Harvard Pilgrim Health Care’s Michael Sherman says.

Helix
Payers Begin To Navigate Gene Therapy For Hemophilia A

BioMarin Pharmaceutical Inc.’s expected high price tag for its gene therapy for hemophilia A, and the fact that data has suggested Roctavian’s effect may have declined over time, was likely prompting some tough questions from payers even before the US Food and Drug Administration decided to delay a decision on approval.

In a move that surprised many stakeholders, FDA sent a complete response letter to the company two days before its...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet